4//SEC Filing
Francis Richard D 4
Accession 0000950170-25-034583
CIK 0000818686other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:03 PM ET
Size
11.6 KB
Accession
0000950170-25-034583
Insider Transaction Report
Form 4
Francis Richard D
President and CEO
Transactions
- Exercise/Conversion
Ordinary Shares
2025-03-04+50,223→ 295,556 total - Sale
Ordinary Shares
2025-03-04$15.73/sh−15,514$244,107→ 280,042 total - Exercise/Conversion
Restricted Share Units
2025-03-04−50,223→ 150,669 total→ Ordinary Shares (50,223 underlying) - Sale
Ordinary Shares
2025-03-05$15.91/sh−8,259$131,427→ 271,783 total
Footnotes (7)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F7]Restricted share units were granted on March 4, 2024, with 50,223 vested on March 4, 2025, and 50,223 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001673277
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:03 PM ET
- Size
- 11.6 KB